AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34399811 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache and nausea/vomiting combination
Number of subjects: 224
Study 34399811 — intervention group
Group type: EXPERIMENTAL
Intervention: Syncope
Number of subjects: 224
Study 34399811 — intervention group
Group type: EXPERIMENTAL
Intervention: Nausea/vomiting (in conscious patients)
Number of subjects: 224
Study 34399811 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache (in conscious patients)
Number of subjects: 224
Study 34399830 — intervention group
Group type: COMPARATOR
Intervention: Acute-stage monocytes (n=75)
Number of subjects: 75
Study 34399830 — intervention group
Group type: COMPARATOR
Intervention: Recovery-stage monocytes (n=56)
Number of subjects: 75
Study 34399830 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-scale model
Number of subjects: 75
Study 34399856 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-conception nutrition and exercise intervention
Number of subjects: 120
Study 34399856 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 34400137 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 448
Study 34400137 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy and lymph node staging without adjuvant therapy
Number of subjects: 448
Study 34400137 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy (plus bilateral salpingo-oophorectomy) alone
Number of subjects: 448
Study 34400140 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal cardiovascular resonance imaging (CMR) findings
Number of subjects: 58
Study 34400140 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 58
Study 34400140 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac troponin T and N-terminal pro-B-type natriuretic peptide concentrations on admission
Number of subjects: 58
Study 34400337 — intervention group
Group type: EXPERIMENTAL
Intervention: Garcinia cambogia alone
Number of subjects: 22
Study 34400337 — intervention group
Group type: EXPERIMENTAL
Intervention: Garcinia cambogia with green tea
Number of subjects: 22
Study 34400337 — intervention group
Group type: EXPERIMENTAL
Intervention: Garcinia cambogia containing HDS
Number of subjects: 22
Study 34400337 — intervention group
Group type: COMPARATOR
Intervention: Control groups (HDS containing green tea without G cambogia and other HDS)
Number of subjects: 22
Study 34400362 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health intervention (Nourish) including skills training, self-monitoring, personalized feedback, and responsive coaching.
Number of subjects: 300
Study 34400362 — intervention group
Group type: COMPARATOR
Intervention: Attention control arm (not specified in detail).
Number of subjects: 300
Study 34400453 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation (cTBS)
Number of subjects: 0
Study 34400453 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 34400453 — intervention group
Group type: EXPERIMENTAL
Intervention: cTBS
Number of subjects: 0
Study 34400454 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive strategy of fluid removal initiated systematically when fluid balance or weight change is positive and patients are clinically stable.
Number of subjects: 410
Study 34400454 — intervention group
Group type: COMPARATOR
Intervention: Curative strategy of fluid removal initiated only in case of weaning failure documented as of cardiac origin.
Number of subjects: 410
Study 34400454 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive strategy
Number of subjects: 410
Study 34400454 — intervention group
Group type: COMPARATOR
Intervention: Curative strategy
Number of subjects: 410
Study 34400568 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult Assisting Hand Assessment Stroke (Ad-AHA)
Number of subjects: 89
Study 34400568 — intervention group
Group type: EXPERIMENTAL
Intervention: Fugl-Meyer Assessment (FMA)
Number of subjects: 89
Study 34400568 — intervention group
Group type: EXPERIMENTAL
Intervention: FMA-SAFE score
Number of subjects: 89
Study 34400574 — intervention group
Group type: EXPERIMENTAL
Intervention: Widespread pain
Number of subjects: 2464
Study 34400574 — intervention group
Group type: COMPARATOR
Intervention: No widespread pain (Control)
Number of subjects: 2464
Study 34400910 — intervention group
Group type: EXPERIMENTAL
Intervention: RIFA quantification method
Number of subjects: 20
Study 34400910 — intervention group
Group type: EXPERIMENTAL
Intervention: RIFA-correlated genes
Number of subjects: 20
Study 34400910 — intervention group
Group type: EXPERIMENTAL
Intervention: Differentially expressed genes analysis
Number of subjects: 20
Study 34400910 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-cell RNA sequencing analysis
Number of subjects: 20
Study 34401374 — intervention group
Group type: EXPERIMENTAL
Intervention: Online cognitive behavior therapy (CBT) targeting avoidance behavior, duration: 8 weeks, with therapist support
Number of subjects: 30
Study 34401394 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard feedback
Number of subjects: 1074
Study 34401394 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored feedback
Number of subjects: 1074
Study 34401394 — intervention group
Group type: COMPARATOR
Intervention: No feedback (control arm)
Number of subjects: 1074
Study 34401600 — intervention group
Group type: EXPERIMENTAL
Intervention: BLZ-100 (tozuleristide) administered intravenously at doses of 1, 3, 6, 12, and 18 mg, 2 days before tumor excision.
Number of subjects: 21
Study 34401600 — intervention group
Group type: EXPERIMENTAL
Intervention: BLZ-100 (tozuleristide) administered intravenously at intermediate doses (3-12 mg).
Number of subjects: 21
Study 34401600 — intervention group
Group type: EXPERIMENTAL
Intervention: BLZ-100 (tozuleristide) administered intravenously.
Number of subjects: 21
Study 34401686 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC) initiated <24 hours after admission
Number of subjects: 279
Study 34401686 — intervention group
Group type: COMPARATOR
Intervention: Standard care including KMC once stable at >24 hours after admission
Number of subjects: 279
Study 34401686 — intervention group
Group type: EXPERIMENTAL
Intervention: KMC initiated <24 hours after admission
Number of subjects: 279
Study 34401690 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intervention via nasogastric tube over 30 min
Number of subjects: 39
Study 34401690 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intervention
Number of subjects: 39
Study 34401690 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intoxication
Number of subjects: 39
Study 34401724 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated digital health system tools including an automated CKD patient registry, risk prediction algorithm, electronic patient-facing values clarification tool, tracking application, and EHR workflow.
Number of subjects: 1032
Study 34401724 — intervention group
Group type: EXPERIMENTAL
Intervention: Values clarification tool
Number of subjects: 1032
Study 34401724 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking application used by nurse case managers
Number of subjects: 1032
Study 34401724 — intervention group
Group type: EXPERIMENTAL
Intervention: Documentation of preferred kidney replacement modality
Number of subjects: 1032
Study 34401724 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health system tools
Number of subjects: 1032
Study 34401861 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin-based lipid therapies and lifestyle intervention for 2 years
Number of subjects: 217
Study 34401888 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 vaccine
Number of subjects: 0
Study 34401888 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 57 Spike IgG
Number of subjects: 0
Study 34401888 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 57 RBD IgG
Number of subjects: 0
Study 34401888 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 57 cID50 neutralization levels
Number of subjects: 0
Study 34401888 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 57 cID80 neutralization levels
Number of subjects: 0
Study 34401888 — intervention group
Group type: EXPERIMENTAL
Intervention: cID50 neutralization titers <2.42, 100, or 1000
Number of subjects: 0
Study 34401888 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 29 cID50 titer
Number of subjects: 0
Study 34402466 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose adalimumab (40 mg weekly, 80 mg every other week or greater)
Number of subjects: 79
Study 34402466 — intervention group
Group type: COMPARATOR
Intervention: Standard adalimumab (40 mg every other week)
Number of subjects: 79
Study 34402466 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 79
Study 34402795 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth-based exercise training (20 weeks of moderate-intensity aerobic training, 5 days a week)
Number of subjects: 3
Study 34402795 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth-based exercise training
Number of subjects: 3
Study 34402876 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized biannual five-hour examination and annual follow-up interviews
Number of subjects: 3289
Study 34402932 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (10 weeks supervised)
Number of subjects: 23
Study 34402932 — intervention group
Group type: COMPARATOR
Intervention: Baseline metabolic assessments
Number of subjects: 23
Study 34403125 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for chronic pain and shared decision-making for prescription opioid dose reduction
Number of subjects: 20
Study 34403803 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 0
Study 34404257 — intervention group
Group type: EXPERIMENTAL
Intervention: Onabotulinum toxin-A
Number of subjects: 32
Study 34404358 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin 1500 mg by mouth twice daily for 12 weeks
Number of subjects: 0
Study 34404358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34404361 — intervention group
Group type: EXPERIMENTAL
Intervention: Morbid obesity
Number of subjects: 202
Study 34404361 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls
Number of subjects: 202
Study 34404361 — intervention group
Group type: EXPERIMENTAL
Intervention: Age increase
Number of subjects: 202
Study 34404378 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom questionnaire
Number of subjects: 50
Study 34404454 — intervention group
Group type: EXPERIMENTAL
Intervention: LEAPS intervention (youth-led ECCE program)
Number of subjects: 1089
Study 34404454 — intervention group
Group type: COMPARATOR
Intervention: Non-randomized youth participant open cohorts
Number of subjects: 1089
Study 34404454 — intervention group
Group type: COMPARATOR
Intervention: LEAPS students (non-randomized school cohort)
Number of subjects: 1089
Study 34404454 — intervention group
Group type: COMPARATOR
Intervention: Implementation evaluation
Number of subjects: 1089
Study 34404454 — intervention group
Group type: COMPARATOR
Intervention: Cost evaluation
Number of subjects: 1089
Study 34404458 — intervention group
Group type: EXPERIMENTAL
Intervention: Explainable Boosting Machine model for prediction of ICU outcomes
Number of subjects: 1039
Study 34404458 — intervention group
Group type: EXPERIMENTAL
Intervention: Explainable Boosting Machine model
Number of subjects: 1039
Study 34404463 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg subcutaneously at baseline, weeks 1, 2, and 3, and every 4 weeks from week 4, combined with a 26-week prednisolone taper regimen.
Number of subjects: 50
Study 34404463 — intervention group
Group type: COMPARATOR
Intervention: Placebo subcutaneously at baseline, weeks 1, 2, and 3, and every 4 weeks from week 4, combined with a 26-week prednisolone taper regimen.
Number of subjects: 50
Study 34404623 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor with supportive care
Number of subjects: 28
Study 34404699 — intervention group
Group type: EXPERIMENTAL
Intervention: Common exercise programme with individualised progression criterion based on neuromuscular capacity
Number of subjects: 0
Study 34404699 — intervention group
Group type: COMPARATOR
Intervention: Current best practice exercise programme for lower limb tendinopathies
Number of subjects: 0
Study 34404711 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute kidney replacement therapy (KRT)
Number of subjects: 108
Study 34404711 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium assessment using the Confusion Assessment Method-ICU (CAM-ICU)
Number of subjects: 108
Study 34404711 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving safety, adverse events, and medication adherence assessment
Number of subjects: 108
Study 34404895 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth (29 studies, 574,649 participants)
Number of subjects: 596128
Study 34404895 — intervention group
Group type: EXPERIMENTAL
Intervention: electronic health records (13 studies, 4534 participants)
Number of subjects: 596128
Study 34404895 — intervention group
Group type: EXPERIMENTAL
Intervention: telemedicine (4 studies, 465 participants)
Number of subjects: 596128
Study 34404895 — intervention group
Group type: EXPERIMENTAL
Intervention: cloud-based application (2 studies, 2382 participants)
Number of subjects: 596128
Study 34404895 — intervention group
Group type: EXPERIMENTAL
Intervention: information communication technology (3 studies, 681 participants)
Number of subjects: 596128
Study 34404895 — intervention group
Group type: EXPERIMENTAL
Intervention: artificial intelligence (1 study, 13,417 participants)
Number of subjects: 596128
Study 34404907 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose infusion
Number of subjects: 50
Study 34404907 — intervention group
Group type: COMPARATOR
Intervention: Water infusion
Number of subjects: 50
Study 34404924 — intervention group
Group type: EXPERIMENTAL
Intervention: Low maternal education
Number of subjects: 911
Study 34404924 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal diabetes
Number of subjects: 911
Study 34404924 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal brain injury
Number of subjects: 911
Study 34404924 — intervention group
Group type: COMPARATOR
Intervention: Small for gestational age
Number of subjects: 911
Study 34404924 — intervention group
Group type: COMPARATOR
Intervention: Weight <10th percentile at 36 weeks
Number of subjects: 911
Study 34405140 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of CD45RA memory T cells
Number of subjects: 0
Study 34405312 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported Employment Demonstration intervention
Number of subjects: 2960
Study 34405312 — intervention group
Group type: EXPERIMENTAL
Intervention: Local economic characteristics (high unemployment rate, rising average wages)
Number of subjects: 2960
Study 34405312 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative reasons for enrollment
Number of subjects: 2960
Study 34405312 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for non-enrollment
Number of subjects: 2960
Study 34405312 — intervention group
Group type: COMPARATOR
Intervention: Comparison of contacted vs. non-contacted samples
Number of subjects: 2960
Study 34405577 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) at doses of 35 Gy, 37.5 Gy, 40 Gy, 42.5 Gy, and 45 Gy in five fractions
Number of subjects: 16
Study 34405577 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Number of subjects: 16
Study 34405965 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 1229
Study 34405965 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 1229
Study 34405965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1229
Study 34405965 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Hispanic Black
Number of subjects: 1229
Study 34405965 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic
Number of subjects: 1229
Study 34405965 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume enrollment (≥10 patients)
Number of subjects: 1229
Study 34405965 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin rash
Number of subjects: 1229
Study 34406051 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34406122 — intervention group
Group type: EXPERIMENTAL
Intervention: Mom and Baby Net intervention
Number of subjects: 184
Study 34406122 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 184
Study 34406124 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based connected devices (CDs) used for monitoring parameters, with education on reacting to abnormal variations; duration of intervention includes 3 months of data collection and 12 months of education and action plan development.
Number of subjects: 36
Study 34406124 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program for patients and training for physicians; personalized action plans developed based on collected data and clinical history.
Number of subjects: 36
Study 34406184 — intervention group
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI PET/CT
Number of subjects: 1
Study 34406184 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Number of subjects: 1
Study 34406184 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided biopsy
Number of subjects: 1
Study 34406372 — intervention group
Group type: EXPERIMENTAL
Intervention: ECLS patients
Number of subjects: 20
Study 34406372 — intervention group
Group type: EXPERIMENTAL
Intervention: High microembolic rate (>100/30 min) in ECLS patients
Number of subjects: 20
Study 34406502 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical low-dose (1,005 mg) preservative-free hydrocortisone, administered twice daily in each eye for 2 weeks.
Number of subjects: 100
Study 34406524 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen Reserve Index (ORI)
Number of subjects: 51
Study 34406524 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-hypoxemic patients)
Number of subjects: 51
Study 34406537 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal lobe epilepsy patients
Number of subjects: 90
Study 34406537 — intervention group
Group type: COMPARATOR
Intervention: Extra-temporal lobe epilepsy patients
Number of subjects: 90
Study 34407054 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab, carboplatin, and paclitaxel every 21 days for six cycles
Number of subjects: 54
Study 34407054 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab, carboplatin, and paclitaxel
Number of subjects: 54
Study 34407260 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mm pen needles combined with education on injection technique
Number of subjects: 171
Study 34407676 — intervention group
Group type: EXPERIMENTAL
Intervention: Silent cerebral infarcts and cerebral vessel stenosis on brain MRI and MRA
Number of subjects: 44
Study 34407735 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin in combination with temsirolimus
Number of subjects: 19
Study 34407844 — intervention group
Group type: EXPERIMENTAL
Intervention: M2698 monotherapy (15-380 mg daily)
Number of subjects: 101
Study 34407844 — intervention group
Group type: EXPERIMENTAL
Intervention: M2698/trastuzumab (160 mg QD)
Number of subjects: 101
Study 34407844 — intervention group
Group type: EXPERIMENTAL
Intervention: M2698/tamoxifen (160 mg QD/240 mg intermittent regimen)
Number of subjects: 101
Study 34407844 — intervention group
Group type: EXPERIMENTAL
Intervention: M2698 (all cohorts)
Number of subjects: 101
Study 34407840 — intervention group
Group type: EXPERIMENTAL
Intervention: Move to Health program, a holistic health intervention tailored for chronic low back pain, involving motivational interviewing and personal health inventory.
Number of subjects: 0
Study 34407972 — intervention group
Group type: EXPERIMENTAL
Intervention: MTL-CEBPA (therapeutic C/EBPα small activating RNA)
Number of subjects: 36
Study 34407972 — intervention group
Group type: EXPERIMENTAL
Intervention: MTL-CEBPA
Number of subjects: 36
Study 34407972 — intervention group
Group type: EXPERIMENTAL
Intervention: MTL-CEBPA combined with checkpoint inhibitors or PMN-MDSC-targeted immunotherapy
Number of subjects: 36
Study 34408044 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi intervention (8 weeks)
Number of subjects: 72
Study 34408044 — intervention group
Group type: COMPARATOR
Intervention: Standard care (booklet on self-management of cancer symptoms)
Number of subjects: 72
Study 34408049 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide fumarate (TAF) monotherapy
Number of subjects: 0
Study 34408049 — intervention group
Group type: COMPARATOR
Intervention: No antiviral treatment (Control)
Number of subjects: 0
Study 34408155 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 144
Study 34408155 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 144
Study 34408155 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 144
Study 34408440 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Number of subjects: 287
Study 34408440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study 34408662 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (45 min cycling at 65% of heart rate reserve)
Number of subjects: 2
Study 34408665 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular Neuromodulation
Number of subjects: 0
Study 34408665 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34408750 — intervention group
Group type: EXPERIMENTAL
Intervention: 6B11-OCIK adoptive cell therapy (autologous T cells induced by 6B11 minibody plus dendritic cells and cytokines)
Number of subjects: 3
Study 34408870 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine Green (ICG) and Near-Infrared (NIR) Fluorescence Imaging
Number of subjects: 0
Study 34408978 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocyte Doubling Time (LDT) >12 months
Number of subjects: 0
Study 34408978 — intervention group
Group type: EXPERIMENTAL
Intervention: LDT ≤ 12 months
Number of subjects: 0
Study 34409288 — intervention group
Group type: EXPERIMENTAL
Intervention: 1MIU low-dose interleukin-2
Number of subjects: 36
Study 34409288 — intervention group
Group type: EXPERIMENTAL
Intervention: 2MIU low-dose interleukin-2
Number of subjects: 36
Study 34409288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36